Canopy Growth Corp
CGCCanopy Growth Corporation, formerly Tweed Marijuana Inc., is a Canadian cannabis company based in Smiths Falls, Ontario. In April 2019, Canopy was the world's largest cannabis company based on the value of all shares or market capitalization. At that time, Constellation Brands Inc. controlled over 35% percent of the company which had approximately 3,200 employees. The year 2019 created new challenges for the company however, with its stock price dropping by about 32%. In the next two years (to the end of 2021) its shares dropped an additional 55%. In September 2022, the company announced divestiture of its Canadian retail operations, selling its 28 retails stores across the country to other cannabis companies.
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How CGC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CHI-554 | Phase 2 | Anxiety | - | - |
Cannabidiol | Phase 2 | Menstrual Discomfort | - | - |
Frequently asked questions
What is in Canopy Growth Corp's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Canopy Growth Corp's (CGC) pipeline across Phase 2. Its lead program is CHI-554 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Canopy Growth Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Canopy Growth Corp (CGC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CGC biotech catalysts?→
Add CGC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Canopy Growth Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.